 CAMBRIDGE, Mass., Jan. 22, 2021 GLOBE NEWSWIRE -- Mersana Therapeutics, Inc. Nasdaq: MRSN, a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates ADCs targeting cancers in areas of high unmet medical need, today announced the grant of an inducement award to the newly appointed Senior Vice President and Chief Human Resources Officer, Carla Poulson. In connection with the appointment, the Compensation Committee of the Board of Directors of Mersana Therapeutics approved a stock option grant to Ms. Poulson as an inducement material to Ms. Poulson entering into employment with Mersana Therapeutics, in accordance with Nasdaq Listing Rule 5635c4. The stock option grant provides for the purchase of up to 100,000 shares of Mersana Therapeutics common stock, at a price of 21.67 per share, the closing price per share of Mersana Therapeutics common stock on the date of grant, and vests over four years, with 25 of the shares vesting on the first anniversary of the Ms. Poulsons employment start date, and the remainder vesting in equal quarterly installments over the following three years, subject to Ms. Poulsons continued employment with Mersana Therapeutics through such applicable vesting dates. 